Federal Register / Vol. 74, No. 8 / Tuesday, January 13, 2009 / Notices 1689 

that each assisted reproductive 

technology (ART) program shall 

annually report to the Secretary through 

the Centers for Disease Control and 

Prevention: (1) Pregnancy success rates 

achieved by such ART program, and (2) 

the identity of each embryo laboratory 

used by such ART program and whether 

the laboratory is certified or has applied 

for such certification under the Act. The 

required information is currently 

reported by ART programs to CDC as 

specified in the Assisted Reproductive 

Technology (ART) Program Reporting 

System (OMB No. 0920–0556, exp. 9/ 

30/2009). CDC seeks to extend OMB 

approval for a period of three years and 

incorporate a minor change in wording 

to one question. In addition, the revised 

total burden estimate includes an 

anticipated increase in the number of 

respondents and a slight decrease in the 

average number of responses per 

respondent. The burden estimate per 

response has also been revised to 

include an adjustment for data 

validation procedures. 

The currently approved program 

reporting system, also known as the 

National ART Surveillance System 

(NASS), includes information about all 

ART cycles initiated by any of the ART 

programs in the United States. An ART 

cycle is considered to begin when a 

woman begins taking ovarian 

stimulatory drugs or starts ovarian 

monitoring with the intent of having 

embryos transferred. The system also 

collects information about the 

pregnancy outcome of each cycle, as 

well as a number of data items deemed 

important to explain variability in 

success rates across ART programs and 

across individuals. Data elements and 

definitions currently in use reflect 

CDC’s consultations with 

representatives of the Society for 

Assisted Reproductive Technology 

(SART), the American Society for 

Reproductive Medicine, and RESOLVE, 

the National Infertility Association (a 

national, nonprofit consumer 

organization), as well as a variety of 

individuals with expertise and interest 

in this field. 

Respondents are the 480 ART 

programs in the United States. 

Approximately 420 clinics are expected 

to report an average of 286 ART cycles 

each. Ten percent of responding clinics 

will be randomly selected to participate 

in full validation of selected ART cycle 

records and an abbreviated validation of 

selected cycles resulting in live birth. 

All information is collected 

electronically. Respondents have the 

option of entering data directly into a 

Web-based NASS interface or of 

transmitting system-compatible files 

extracted from other record systems. 

The ART program reporting system 

allows CDC to publish an annual report 

to Congress as specified by the FCSRCA 

and to provide information needed by 

consumers. 

There are no costs to respondents 

other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average burden 

per response 

(in hours) 

Total burden 

(in hours) 

ART Programs ...................................... NASS .................... 420 286 38/60 76,076 

Dated: January 2, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E9–405 Filed 1–12–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Subcommittee on Procedures 

Reviews, Advisory Board on Radiation 

and Worker Health (ABRWH), National 

Institute for Occupational Safety and 

Health (NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention, announces the 

following meeting for the 

aforementioned subcommittee: 

Time and Date: 9:30 a.m.–5 p.m., January 

28, 2009. 

Place: Cincinnati Airport Marriott, 2395 

Progress Drive, Hebron, Kentucky 41018. 

Telephone (859) 334–4611, Fax (859) 334– 

4619. 

Status: Open to the public, but without a 

public comment period. To access by 

conference call dial the following 

information 1(866) 659–0537, Participant 

Pass Code 9933701. 

Background: The Advisory Board was 

established under the Energy Employees 

Occupational Illness Compensation Program 

Act of 2000 to advise the President on a 

variety of policy and technical functions 

required to implement and effectively 

manage the new compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines that have 

been promulgated by the Department of 

Health and Human Services (HHS) as a final 

rule; advice on methods of dose 

reconstruction which have also been 

promulgated by HHS as a final rule; advice 

on the scientific validity and quality of dose 

estimation and reconstruction efforts being 

performed for purposes of the compensation 

program; and advice on petitions to add 

classes of workers to the Special Exposure 

Cohort (SEC). 

In December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, which 

subsequently delegated this authority to CDC. 

NIOSH implements this responsibility for 

CDC. The charter was issued on August 3, 

2001, renewed at appropriate intervals, and 

will expire on August 3, 2009. 

Purpose: The Advisory Board is charged 

with (a) Providing advice to the Secretary, 

HHS, on the development of guidelines 

under Executive Order 13179; (b) providing 

advice to the Secretary, HHS, on the 

scientific validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advise the Secretary on 

whether there is a class of employees at any 

Department of Energy facility who were 

exposed to radiation but for whom it is not 

feasible to estimate their radiation dose, and 

on whether there is reasonable likelihood 

that such radiation doses may have 

endangered the health of members of this 

class. The Subcommittee on Procedures 

Reviews was established to aid the Advisory 

Board in carrying out its duty to advise the 

Secretary, HHS, on dose reconstruction. It 

will be responsible for overseeing, tracking, 

and participating in the reviews of all 

procedures used in the dose reconstruction 

process by the NIOSH Office of 

Compensation Analysis and Support (OCAS) 

and its dose reconstruction contractor. 

Matters To Be Discussed: The agenda for 

the Subcommittee meeting includes: a 

discussion of proposed new versions of the 

computer-assisted telephone interview 

scripts and procedures NIOSH uses to 

interview claimants at the outset of the dose 

reconstruction process; a discussion of 

ORAUT–OTIB–0054 (‘‘Fission and 

Activation Product Assignment for Internal 

Dose-Related Gross Beta and Gross Gamma 

Analyses’’) and ORAUT–OTIB–0066 

(‘‘Calculation of Dose from Intakes of Special 

Tritium Compounds’’); and, a continuation of 

the comment-resolution process for other 

dose reconstruction procedures under review 

by the Subcommittee. 

1690 Federal Register / Vol. 74, No. 8 / Tuesday, January 13, 2009 / Notices 

The agenda is subject to change as 

priorities dictate. 

In the event an individual cannot attend, 

written comments may be submitted. Any 

written comments received will be provided 

at the meeting and should be submitted to 

the contact person below well in advance of 

the meeting. 

Contact Person for More Information: 

Theodore Katz, Executive Secretary, NIOSH, 

CDC, 1600 Clifton Road, Mailstop E–20, 

Atlanta, Georgia 30333, Telephone (513) 

533–6800, Toll Free 1 (800) CDC–INFO, email ocas@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: January 7, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–524 Filed 1–12–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: Child Care Quarterly Case 

Record Report—ACF–801. 

OMB No.: 0970–0167. 

Description: Section 658K of the Child 

Care and Development Block Grant Act 

of 1990 (Pub. L. 101–508, 42 U.S.C. 

9858) requires that States and 

Territories submit monthly case-level 

data on the children and families 

receiving direct services under the Child 

Care and Development Fund. The 

implementing regulations for the 

statutorily required reporting are at 45 

CFR 98.70. Case-level reports, submitted 

quarterly or monthly (at grantee option), 

include monthly sample or full 

population case-level data. The data 

elements to be included in these reports 

are represented in the ACF–801. ACF 

uses disaggregate data to determine 

program and participant characteristics 

as well as costs and levels of child care 

services provided. This provides ACF 

with the information necessary to make 

reports to Congress, address national 

child care needs, offer technical 

assistance to grantees, meet performance 

measures, and conduct research. 

Consistent with the statute and 

regulations, ACF requests extension of 

the ACF–801. With this extension, ACF 

is proposing several changes and 

clarifications to the reporting 

requirements and instructions. 

Respondents: States, the District of 

Columbia, and Territories including 

Puerto Rico, Guam, the Virgin Islands, 

American Samoa, and the Northern 

Mariana Islands. 

ANNUAL BURDEN ESTIMATES

Instrument 

Number 

of respondents 

Number 

of responses 

per respondent 

Average 

burden 

hours per 

response 

Total burden hours 

ACF–801 .......................................................................................................................................... 56 4 20 4,480 

Estimated Total Annual Burden 

Hours: 4,480 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Administration, Office of Information 

Services, 370 L’Enfant Promenade, SW., 

Washington, DC 20447, Attn: ACF 

Reports Clearance Officer. All requests 

should be identified by the title of the 

information collection. E-mail address: 

infocollection@acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Fax: 202–395–6974, 

Attn: Desk Officer for the 

Administration for Children and 

Families. 

Dated: January 8, 2009. 

Janean Chambers, 

Reports Clearance Officer. 

[FR Doc. E9–447 Filed 1–12–09; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0038] 

Advisory Committees; Tentative 

Schedule of Meetings for 2009 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing a 

tentative schedule of forthcoming 

meetings of its public advisory 

committees for 2009. During 1991, at the 

request of the Commissioner of Food 

and Drugs (the Commissioner), the 

Institute of Medicine (the IOM) 

conducted a study of the use of FDA’s 

advisory committees. In its final report, 

one of the IOM’s recommendations was 

for the agency to publish an annual 

tentative schedule of its meetings in the 

Federal Register. This publication 

implements the IOM’s recommendation. 

FOR FURTHER INFORMATION CONTACT: 

Theresa L. Green, Advisory Committee 

Oversight and Management Staff (HF– 

4), Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20857, 

301–827–1220. 

SUPPLEMENTARY INFORMATION: The IOM, 

at the request of the Commissioner, 

undertook a study of the use of the 

FDA’s advisory committees. In its final 

report in 1992, one of the IOM’s 

recommendations was for FDA to adopt 

a policy of publishing an advance yearly 

schedule of its upcoming public 

advisory committee meetings in the 

Federal Register; FDA has implemented 

this recommendation. The annual 

publication of tentatively scheduled 

advisory committee meetings will 

provide both advisory committee 

members and the public with the 

opportunity, in advance, to schedule 

attendance at FDA’s upcoming advisory 

committee meetings. Because the 

schedule is tentative, amendments to 

this notice will not be published in the 

Federal Register. However, changes to 

the schedule will be posted on the FDA